🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05692674
Recruiting Phase 2

A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction

NCT05692674 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Proton and Heavy Ion Center
Phase
Phase 2
Started
2023-01-10
Last updated
2023-01-20

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

adjuvant hypofractionated intensity-modulated proton radiotherapy

adjuvant hypofractionated intensity-modulated proton radiotherapy: CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;

Study summary

The incidence of breast reconstruction failure after conventional photon radiotherapy for breast cancer is about 18.7%. At present, there is limited data on proton radiotherapy for post operative breast cancer with implantation reconstruction. Proton radiotherapy for breast cancer can significantly reduce the radiation dose of the ipsilateral heart and lung, thereby reducing the incidence of cardiac events and radiation pneumonia. This study is aimed at the study of adjuvant hypofractionated intensity-modulated proton radiotherapy for post operative breast cancer with implantation reconstruction. It can provide an ideal treatment option for such patients to effectively protect the heart and lungs without increasing the failure rate of breast reconstruction after adjuvant radiotherapy.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * 1: Patients with pathologically confirmed breast cancer 2: Indications: patients who need adjuvant radiotherapy after mastectomy and implant reconstruction 3: No distant metastasis 4: Had no chest and breast radiotherapy history 5: Between the ages of 18 and 80 6: ECOG general status score is 0-2,There are no serious pulmonary hypertension, cardiovascular disease, peripheral vascular disease, serious chronic heart disease and other complications that may affect the radiotherapy 7: Non pregnancy (confirmed by serum or urine β- HCG test) or lactating women 8: The patient must sign the informed consent form for receiving radiotherapy. Exclusion Criteria: * 1: No pathological confirmation; 2: Distant metastasis; 3: Had chest and breast radiotherapy history 4: Organs at risk could not achieve safe dose 5: Pregnancy (confirmed by serum or urine β- HCG test) or lactating women 6: Poor general health status, i.e. KPS\<70, or ECOG\>2 7: There are serious complications that may affect the radiotherapy, including: a) unstable angina, congestive heart failure and myocardial infarction requiring hospitalization in the past 6 months; b) Acute bacterial or systemic fungal infection;c) Chronic obstructive pulmonary disease exacerbation or other respiratory diseases need hospitalization; d) Patients with immunosuppression;e) With connective tissue disease, such as active scleroderma or lupus and other contraindications to radiotherapy; 8: Unable to understand the purpose of treatment or unwilling/unable to sign informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Proton and Heavy Ion center Shanghai Shanghai Municipality Recruiting

More Shanghai Proton and Heavy Ion Center trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05692674 on ClinicalTrials.gov ↗ ← All trials in China